We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » U.S. FDA Guidance Clarifies When Postmarket Studies Are Needed
U.S. FDA Guidance Clarifies When Postmarket Studies Are Needed
The U.S. Food and Drug Administration may approve devices whose benefit-to-risk ratio is less certain if that uncertainty is “sufficiently balanced” by factors such as postmarket controls, the agency says in an April 23 draft guidance.
To View This Article:
Login
Subscribe To International Medical Device Regulatory Monitor